News

Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital (“Gurnet Point”), a…
Read More...

Takeda, Zedira and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac…
Read More...

Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to…
Read More...

AbbVie announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target…
Read More...

Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to…
Read More...

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple…
Read More...

Zymeworks Inc. announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted…
Read More...

Telesis Bio and Cellibre announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp Digital-to-Biological Converter (DBC)…
Read More...

Ginkgo Bioworks and Zymergen announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform…
Read More...

PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, announced the closing of a $35 million Series A financing…
Read More...

Ayala Pharmaceuticals, Inc. (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and…
Read More...

Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases,…
Read More...

Verseon International Corporation, the company leading a technology-driven transformation of the pharmaceutical industry, announces that it has acquired Edammo, Inc. Verseon has…
Read More...

Eli Lilly and Company and Akouos, Inc. announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of…
Read More...

Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy announced that the Company has signed an exclusive…
Read More...

Kite, a Gilead Company announces that the European Commission (EC) has granted approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with…
Read More...

ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is…
Read More...

Immune-Onc Therapeutics, Inc., a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced the dosing of the first…
Read More...

Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using…
Read More...

Oculis, SA. a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp, a special…
Read More...